Novo Nordisk is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy copycats, with rare exceptions.
Related Posts
Xi wants to boost China’s advanced manufacturing prowess — and Trump may not like it
Beijing’s renewed commitment to advanced manufacturing could run counter to Trump’s core demands in the ongoing trade talks.
Microsoft stock slumps 5% on disappointing revenue outlook
Microsoft shares dropped 5% despite topping fiscal second-quarter estimates due to weak guidance.
CVS posts mixed results, holds off on guidance in Joyner’s first earnings report as CEO
CVS expects elevated medical costs to continue to pressure its performance this year, “and as a result we are not providing a formal outlook at […]